Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) EBIT (2016 - 2025)

Historic EBIT for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $54.9 million.

  • Ligand Pharmaceuticals' EBIT rose 164772.51% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 20731.92%. This contributed to the annual value of -$22.6 million for FY2024, which is 28929.83% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported EBIT of $54.9 million as of Q3 2025, which was up 164772.51% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' EBIT ranged from a high of $54.9 million in Q3 2025 and a low of -$36.2 million during Q1 2025
  • Its 5-year average for EBIT is $6.5 million, with a median of $3.1 million in 2024.
  • Over the last 5 years, Ligand Pharmaceuticals' EBIT had its largest YoY gain of 164772.51% in 2025, and its largest YoY loss of 131204.82% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' EBIT (Quarter) stood at $37.7 million in 2021, then crashed by 153.33% to -$20.1 million in 2022, then soared by 83.29% to -$3.4 million in 2023, then plummeted by 186.99% to -$9.6 million in 2024, then soared by 670.0% to $54.9 million in 2025.
  • Its EBIT was $54.9 million in Q3 2025, compared to $8.4 million in Q2 2025 and -$36.2 million in Q1 2025.